Metastatic Ureter Urothelial Carcinoma Recruiting Phase 1 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0110110 (Metastatic Ureter Urothelial Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02496208Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsTreatment